OncUpdates· @OncUpdates · X·· 2026-04-19Score60
Reading
KRAS / RAS targeting: from platform to Phase 3
daraxonrasib ± GnP · mono ORR 47%; +GnP ORR 55%, DCR 90%
Body
@SuyogCancer
has an excellent breakdown below of some of the key studies being presented at #AACR26 in #PancreaticCancer
#CancerResearch #Oncology #OncTwitter
@AACR
Heat 0 · 0 likes · 0 replies · 0 reposts
Source: OncUpdates · x.com